A Phase 4 interventional study of Valsartan/Amlodipine and Nifedipine in Hypertension, sponsored by Novartis. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-06-01.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 35th largest by enrollment of the 139 interventional ones that give a count, is one of 3 that started in 2010, is one of 67 in phase 4, and was the 108th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 564 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 70th largest by enrollment of the 222 interventional ones that give a count, is one of 11 that started in 2010, is one of 67 in phase 4, and was the 187th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to compare the efficacy and safety of Valsartan/Amlodipine (EXforge®) with nifedipine, as well as vascular function index.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
Drug: Valsartan/Amlodipine
Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
Drug: Nifedipine
Drug pages: Valsartan · Amlodipine
Valsartan/Amlodipine 80/5mg single pill combination (SPC)
Also known as: Exforge®
Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
Also known as: Adalat
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at the Study End Point (12 Weeks)
The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher mean sitting diastolic blood pressure (MSDBP) was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis.
Time frame: Baseline, 12 weeks
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at the Study End Point (12 Weeks)
The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher msDBP was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis.
Time frame: Baseline, 12 weeks
Percentage of Patients With Effective Systolic Blood Pressure (SBP) Control Rate and Effective Diastolic Blood Pressure (DBP) Control Rate at the Study End Point (12 Weeks)
Effective SBP control rate was defined as proportion of subjects in whom MSSBP \< 140 mmHg or MSSBP reduction ≥ 20 mmHg from baseline. Effective DBP control rate was defined as proportion of subjects in whom MSDBP \< 90 mmHg or MSDBP reduction ≥10 mmHg from baseline.
Time frame: Baseline, 12 weeks
Percentage of Patients in Whom Blood Pressure Target Was Achieved at the Study End Point at 12 Weeks
Blood Pressure (BP) target was defined as mean sitting BP\<140/90 mm Hg in non-diabetic patients and\<130/80 mm Hg in diabetic patients at 12 weeks.
Time frame: 12 weeks
Change From Baseline in Orthostatic SBP and DBP at 12 Weeks
The arm with higher sitting blood pressure was selected for all examinations throughout the study. Orthostatic blood pressure was measured when subject stood for 1 minute. Orthostatic blood pressures were measured at screening and each visit.
Time frame: Baseline, 12 weeks
Change From Baseline in Sitting Pulse at 12 Weeks
Sitting pulse was measured by sphygmomanometer after subject sat for 5 minutes at clinic during each visit.
Time frame: Baseline, 12 weeks
Change From Baseline in Orthostatic Pulse at 12 Weeks
Orthostatic pulse was measured by sphygmomanometer when subject stood for 1 minute at clinic during each visit.
Time frame: Baseline, 12 weeks
| Milestone | Valsartan/Amlodipine | Nifedipine |
|---|---|---|
| Started | 282 | 282 |
| Intention to treat (itt) | 272 | 268 |
| Completed | 264 | 249 |
| Not completed | 18 | 33 |
| Withdrew: Non-effective therapy | 1 | 4 |
| Withdrew: Ae including clinical laboratory ae | 2 | 8 |
| Withdrew: Hypotension | 1 | 0 |
| Withdrew: Lost to follow-up | 7 | 9 |
| Withdrew: Non-compliance to concomitant medication | 0 | 2 |
| Withdrew: Investigator initiation withdrawal,other | 1 | 1 |
| Withdrew: Withdrawal consent | 1 | 1 |
| Withdrew: Subject initiation withdrawal, other | 5 | 8 |
The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher mean sitting diastolic blood pressure (MSDBP) was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis.
| mm Hg | Valsartan/Amlodipine | Nifedipine |
|---|---|---|
| Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at the Study End Point (12 Weeks) | -16.8 ± 11.69 | -10.6 ± 12.02 |
The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher msDBP was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis.
| mm Hg | Valsartan/Amlodipine | Nifedipine |
|---|---|---|
| Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at the Study End Point (12 Weeks) | -8.5 ± 8.52 | -4.8 ± 8.89 |
Effective SBP control rate was defined as proportion of subjects in whom MSSBP \< 140 mmHg or MSSBP reduction ≥ 20 mmHg from baseline. Effective DBP control rate was defined as proportion of subjects in whom MSDBP \< 90 mmHg or MSDBP reduction ≥10 mmHg from baseline.
| Percentage of participants | Valsartan/Amlodipine | Nifedipine |
|---|---|---|
| Achieving Effective SBP Control | 82.40 | 63.40 |
| Achieving Effective DBP Control | 92.88 | 76.98 |
Blood Pressure (BP) target was defined as mean sitting BP\<140/90 mm Hg in non-diabetic patients and\<130/80 mm Hg in diabetic patients at 12 weeks.
| Percentage of participants | Valsartan/Amlodipine | Nifedipine |
|---|---|---|
| Percentage of Patients in Whom Blood Pressure Target Was Achieved at the Study End Point at 12 Weeks | 79.03 | 57.36 |
The arm with higher sitting blood pressure was selected for all examinations throughout the study. Orthostatic blood pressure was measured when subject stood for 1 minute. Orthostatic blood pressures were measured at screening and each visit.
| mm Hg | Valsartan/Amlodipine | Nifedipine |
|---|---|---|
| Orthostatic diastolic blood pressure | -7.2 ± 9.43 | -3.3 ± 9.58 |
| Orthostatic systolic blood pressure | -13.3 ± 13.86 | -8.6 ± 13.98 |
Sitting pulse was measured by sphygmomanometer after subject sat for 5 minutes at clinic during each visit.
| beats/min | Valsartan/Amlodipine | Nifedipine |
|---|---|---|
| Change From Baseline in Sitting Pulse at 12 Weeks | -1.1 ± 8.49 | 0.0 ± 8.22 |
Orthostatic pulse was measured by sphygmomanometer when subject stood for 1 minute at clinic during each visit.
| beats/min | Valsartan/Amlodipine | Nifedipine |
|---|---|---|
| Change From Baseline in Orthostatic Pulse at 12 Weeks | -0.6 ± 8.93 | 0.4 ± 8.48 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan/Amlodipine | — | 0/282 (0%) | 14/282 (5%) |
| Nifedipine | — | 1/282 (0.4%) | 32/282 (11.3%) |
| Event | Valsartan/Amlodipine | Nifedipine |
|---|---|---|
| Unstable Blood PressureCardiac disorders | 0/282 | 1/282 |
| Event | Valsartan/Amlodipine | Nifedipine |
|---|---|---|
| HeadacheNervous system disorders | 6/282 | 20/282 |
| DizzyNervous system disorders | 11/282 | 15/282 |
| Age Continuous(years) | Valsartan/Amlodipine | Nifedipine | Total |
|---|---|---|---|
| Mean | 53.8 ± 8.59 | 53.1 ± 8.72 | 53.5 ± 8.63 |
| Sex: Female, Male(Participants) | Valsartan/Amlodipine | Nifedipine | Total |
|---|---|---|---|
| Female | 135 | 135 | 270 |
| Male | 137 | 133 | 270 |
The record gives a start of May 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Amlodipine